Nutrition

Cigna covers Ginger’s mental health app as in-network benefit 

  • by

Insurer Cigna plans to cover mental health startup Ginger’s coaching services as a covered benefit. Investors are pouring more funds into mental health startups as they companies and insurers alike look for more ways to meet people’s care needs during a challenging year. 

Sleep Apnea: New Treatment Options You Should Know About

  • by

Sleep Apnea: New Treatment Options You Should Know About One obstacle to diagnosis of sleep apnea is patient fear of treatment options. They may not know that more patient-centric options are now available. The Doctor Weighs In

Biden to Send Coronavirus Vaccine Abroad

  • by

President Biden will send up to 60 million doses of AstraZeneca’s vaccine to countries pleading for help, but some see a medicine dropper for “a four-alarm fire.”

Glytec Raises $21M to Fix Hospital Insulin Management

  • by

What You Should Know: – Glytec announced $21M in funding today from Silicon Valley Bank, Savitr Capital and others to help address the challenge that 90% of hospitals in the U.S. face with insulin management. – Glytec’s insulin management solution, eGMS helps providers track blood glucose data, detect and alert patients in glycemic disarray, provide personalized… Read More »Glytec Raises $21M to Fix Hospital Insulin Management

BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rival

  • by

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. The company thinks the data from the first-in-class tyrosine kinase 2 inhibitor are strong enough to file with regulators, setting up… Read More »BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rival

Crohn’s Disease Is on the Rise

  • by

Many think the abdominal disorder starts in childhood, but it can occur at any age and is becoming more prevalent throughout the world.

Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

  • by

Shots: The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed, qd) vs vehicle (qd) in 1,025 patients aged 18-75yrs. with plaque psoriasis Results: 2EPs & PRO, @12wks., PASI90 (18.8% and 20.9%) vs (1.6% and 2.5%), ≥4-point NRS improvement (67.5% and… Read More »Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

GW Pharmaceuticals’ Epidyolex (cannabidiol) Receives EC’s Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex

  • by

Shots: The approval is based on P-III study evaluating cannabidiol (25 mg/kg/day) vs PBO in patients aged ≥2yrs. as an adjunctive treatment of seizures associated with TSC The study met its 1EPs i.e reduction in seizure frequency (49% vs 27%). The 2EPs supports the effects… Read More »GW Pharmaceuticals’ Epidyolex (cannabidiol) Receives EC’s Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex

Zogenix Presents Results of Fintepla’s (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients, Caregivers, and Families at AAN 2021

  • by

Shots: The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families Results: seizure-related benefits noted by caregivers include a reduction in frequency, seizure activity, and shorter… Read More »Zogenix Presents Results of Fintepla’s (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients, Caregivers, and Families at AAN 2021

Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021

  • by

Shots: The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage RRMS, low annualized relapse rate, improvement in EDSS score The post-hoc analysis of P-III ORATORIO study of Ocrevus vs PBO… Read More »Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021

New Research Highlights ‘Surprising’ Findings About COVID-19’s Impact on Mortality in Community, Long-Term Care Settings

  • by

Since last spring, there has been a consistent — and justifiable — narrative that long-term care residents are particularly vulnerable to the deadly COVID-19 virus. New research, however, suggests it’s not so simple. A team of researchers from the Cleveland Clinic and Health Data Analytics… Read More »New Research Highlights ‘Surprising’ Findings About COVID-19’s Impact on Mortality in Community, Long-Term Care Settings

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

  • by

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI… Read More »Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

  • by

Shots: The 2-year data from Part 2 of P-II/III FIREFISH study involves assessing Evrysdi in 41 infants aged 1-7mos. with symptomatic Type 1 SMA Results: improvement in maintained motor function b/w 12-24mos., babies were able to sit without support for at least 5sec. after 24mos.… Read More »Genentech Presents Results of Two-Year Data for Evrysdi (risdiplam) in Infants with Type 1 SMA at AAN2021

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

  • by

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China,… Read More »Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

The Fascinating History of the Color Red

  • by

The Fascinating History of the Color Red The color red was most likely the first color (besides black and white) to be registered in our ancient ancestors brains. The Doctor Weighs In

Medtronic Launches World’s First 7-Day Wear Infusion Set to Reduce Burden for People with Diabetes

  • by

What You Should Know: – Medtronic has announced the launch of the world’s first and only infusion set that can be worn for up to seven days (instead of the typical three) in select European countries. The infusion set is responsible for delivering insulin from… Read More »Medtronic Launches World’s First 7-Day Wear Infusion Set to Reduce Burden for People with Diabetes

Cleveland Clinic researchers measure pandemic’s effect on Medicare population

  • by

Research conducted by the Cleveland Clinic and Massachusetts-based startup Health Data Analytics Institute (HDAI) measured the difference in mortality during the pandemic  between people covered by Medicare in long-term care facilities and in the community. While a Covid-19 diagnosis increased deaths in both settings, there… Read More »Cleveland Clinic researchers measure pandemic’s effect on Medicare population

TytoCare & GIVA Care Partner to Bring Telehealth to Ukraine

  • by

What You Should Know: – TytoCare has partnered with GIVA Care Group, a leading healthcare distribution company, to bring its all-in-one remote examination solution to the Ukrainian healthcare industry. – The partnership with GIVA Care will mark the first implementation of the TytoCare telehealth solution in Eastern Europe. As the sole distributor of TytoCare in Ukraine, GIVA Care is making the solution available to local physicians and healthcare… Read More »TytoCare & GIVA Care Partner to Bring Telehealth to Ukraine

Fitbit tests if smartwatch could measure blood pressure

  • by

Fitbit is launching a trial to see if its its newest smartwatch could use pulse arrival time to measure blood pressure. Other wearable companies have tried to add wrist-based blood pressure features to their devices, but so far, they have limited accuracy. 

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

  • by

Shots: Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21 Biogen to get exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries… Read More »Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar, tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

COVID-19 Pandemic-Related Excess Mortality and Potential Years of Life Lost in the U.S. and Peer Countries

  • by

A new issue brief reviews excess death rates in the U.S. and peer countries by age groups to examine how the pandemic has affected excess mortality rate among younger people. The analysis looks specifically at the excess deaths that arose in 2020 to examine how… Read More »COVID-19 Pandemic-Related Excess Mortality and Potential Years of Life Lost in the U.S. and Peer Countries

Compared to Peer Countries, the U.S. Had the Highest Rate of Mortality Among People Under Age 65 and Potential Years of Life Lost in 2020 due to the Pandemic

  • by

A new KFF issue brief examines 2020 data on excess mortality – the number of deaths above what is expected in a typical year – and finds that among similarly large and wealthy nations, the United States had the highest premature excess mortality rate in… Read More »Compared to Peer Countries, the U.S. Had the Highest Rate of Mortality Among People Under Age 65 and Potential Years of Life Lost in 2020 due to the Pandemic

The world’s poorest countries are at India’s mercy for vaccines. It’s unsustainable | Achal Prabhala and Leena Menghaney

  • by

This is what happens when a third of humanity depends on one manufacturer for Covid jabs. We need to waive patents now As the UK’s vaccination programme was “knocked off course” due to a delay in receiving five million doses of the AstraZeneca vaccine from… Read More »The world’s poorest countries are at India’s mercy for vaccines. It’s unsustainable | Achal Prabhala and Leena Menghaney

Skyever Pharmaceuticals Pvt.ltd.

  • by

Skyever Pharmaceutical Pvt Ltd Address : Plot No 121, Phase-1 Panchkula Haryana, India) Skyever Pharmaceutical Pvt. Ltd. is an emerging, global pharmaceutical company………. PCD Franchise Companies | Best Pharma Franchise Company | Top Pharma Pcd Pharma Companies | Products Franchise … Continue reading → The… Read More »Skyever Pharmaceuticals Pvt.ltd.

Helius Medical’s PoNS Receives the US FDA’s Approval to Improve Gait in Multiple Sclerosis Patients

  • by

Shots: The approval is based on two clinical studies and a retrospective analysis of RWD. The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients aged ⥸22yrs. The approval will help in improving the… Read More »Helius Medical’s PoNS Receives the US FDA’s Approval to Improve Gait in Multiple Sclerosis Patients

Scotwin Healthcare

  • by

  Scotwin Healthcare Address : Nagal, Suketi Road, Kala amb Distt., Sirmour -173030(H.P) Scotwin Healthcare Pvt. Ltd. is an emerging, global pharmaceutical company………. PCD Franchise Companies | Best Pharma Franchise Company | Top Pharma Pcd Pharma Companies | Products Franchise … Continue reading → The… Read More »Scotwin Healthcare

OIG: Pandemic forced hospitals into ‘survival mode’

  • by

A new report from the HHS’ Office of Inspector General lays bare the varied challenges hospitals faced in the past year — and continue to face. These range from challenges in healthcare delivery to staffing shortages to shaky finances.

Mental health startup Ginger raises $100M 

  • by

Ginger, a startup that connects users with mental health coaches and therapists, raised $100 million in funding. The company is shifting to a risk-based model as it expands.

Covid-19 long-hauler clinics offer a ‘medical home’ for patients on uncharted journey

  • by

There is a growing demand for centralized care for Covid-19 long-haulers — that is, patients who had Covid-19 and recovered but continue to experience symptoms. Health systems are setting up clinics specifically for this patient population, which comes with its own set of opportunities and… Read More »Covid-19 long-hauler clinics offer a ‘medical home’ for patients on uncharted journey

Recipe for Ribollita

  • by

I’m excited to share a recipe from The How Not to Diet Cookbook. If you’ve already made this dish, please leave us a comment on the recipe page or the Instagram post. I’d love to know what you thought about it! Ribollita with White Beans… Read More »Recipe for Ribollita

Unite Us Nabs $150M, Reaching $1.6B Valuation to Address Social Determinants of Health

  • by

What You Should Know: –   Unite Us, the tech company creating coordinated care networks nationwide, has just announced a $150M Series C round of funding led by ICONIQ Capital, bringing its valuation at $1.65 billion.   – Unite Us is leading the care transformation movement towards whole-person health… Read More »Unite Us Nabs $150M, Reaching $1.6B Valuation to Address Social Determinants of Health

BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

  • by

Shots: The BTD is based on a P-Ib/II TRANQUILITY study assessing BXCL501 in patients with acute treatment of agitation associated with dementia, including AD The results demonstrated significant reductions in agitation measures @2hrs. post-dose with both 30 and 60 mcg doses as measured by multiple… Read More »BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan

  • by

Shots: The submission is based on P-III HELP study evaluating lanadelumab (300mg, q2w & q4w) vs PBO in 125 patients with HAE attack for 26wks. It also based on P-III HELP OLE study and interim results of P-III study that evaluated lanadelumab in Japanese patients.… Read More »Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan

Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan

  • by

Shots: The submission is based on P-III HELP study evaluating lanadelumab (300mg, q2w & q4w) vs PBO in 125 patients with HAE attack for 26wks. It also based on P-III HELP OLE study and interim results of P-III study that evaluated lanadelumab in Japanese patients.… Read More »Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan

Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan

  • by

Shots: The submission is based on EV-301 and EV-201 trials in Japan. The P-III EV-301 trial assessing Enfortumab Vedotin vs CT in ~ 600 patients with LA/m-UC, prior treated with platinum-based CT and PD-1/L1 inhibitor The P-II EV-201 trial assessing Enfortumab Vedotin in ~128 patients… Read More »Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan

‘Par for the Course’: Why Hospital-at-Home Models Took So Long to Catch On

  • by

“This really isn’t a new model.” That’s what many home-based care operators and health systems think after they’re asked about the recent hospital-at-home boom in the U.S. In actuality, hospital-at-home models surfaced in the 1990s. Early adopters included Johns Hopkins University, which pioneered its own… Read More »‘Par for the Course’: Why Hospital-at-Home Models Took So Long to Catch On

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

  • by

Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and… Read More »Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

Is Olive Oil Good for You?

  • by

“Is olive oil good for you?” That’s probably not a question that crosses your mind when you grab that bottle of olive oil to cook with. Olive oil is ubiquitous, after all. It’s the go-to oil for almost any recipe, whether you’re cooking something savory… Read More »Is Olive Oil Good for You?

How to Reduce Your TMAO Levels

  • by

Should we be concerned about high-choline plant foods such as broccoli producing the same toxic TMAO that results from eating high-choline animal foods such as eggs? Choline- and carnitine-rich foods—meat, eggs, and dairy—can be converted by our gut flora into trimethylamine, which in our livers… Read More »How to Reduce Your TMAO Levels

Sorting Out How Politics, Policies Figure in Flap Over New York Nursing Home Covid Death Rates

  • by

The plaudits have faded for New York Gov. Andrew Cuomo. Once hailed as a paragon of pandemic governing, he’s since come under scorching criticism for undercounting the state’s covid deaths among nursing home residents by as much as half. The tallying flap drew attention to… Read More »Sorting Out How Politics, Policies Figure in Flap Over New York Nursing Home Covid Death Rates

Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

  • by

With covid vaccines expected to remain scarce into early spring, Connecticut has scrapped its complicated plans to prioritize immunizations for people under 65 with certain chronic conditions and front-line workers. Instead, the state will primarily base eligibility on age. Gov. Ned Lamont pointed to statistics… Read More »Connecticut Is Doling Out Vaccines Based Strictly on Age. It’s Simpler, but Is it Fair?

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

  • by

 Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative, advanced breast cancer with a PIK3CA mutation in… Read More »Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

BridgeBio and Origin’s Nulibry (fosdenopterin) Receives the US FDA’s Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

  • by

Shots: The FDA has approved Nulibry based on three clinical trials compared to data from a natural history study in patients with MoCD Type A The results from three clinical trials showed improvement in overall survival and an 82% reduction in the risk of death,… Read More »BridgeBio and Origin’s Nulibry (fosdenopterin) Receives the US FDA’s Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A